Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)
China flag China · Delayed Price · Currency is CNY
10.38
+0.03 (0.29%)
Feb 4, 2026, 3:00 PM CST

Zhejiang Starry Pharmaceutical Company Description

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally.

It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadobenate dimeglumine injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, ioversol, iopromide, iomeprol, gadobenate dimeglumine, gadobutrol, and other products; quinolone APIs and intermediates, such as levofloxacin and levofloxacin hydrochloride; and CMO/CDMO APIs and intermediates, including CIBA, OPAA, 3N, ILC, JSQ, iodine, aza, and loxoprofen sodium.

It also engages in technology promotion and application; investment; physical education; and wholesale activities.

Zhejiang Starry Pharmaceutical Co.,Ltd. was incorporated in 1997 and is headquartered in Taizhou, China.

Zhejiang Starry Pharmaceutical Co.,Ltd.
CountryChina
Founded1997
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees1,754
CEOWeiyi Shen

Contact Details

Address:
Modern Industrial Centralization Zone
Taizhou, 317306
China
Phone86 576 8771 8628
Websitestarrypharm.com

Stock Details

Ticker Symbol603520
ExchangeShanghai Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyCNY
ISIN NumberCNE1000026N8
SIC Code2833

Key Executives

NamePosition
Weiyi ShenVice Chairman and GM
Junfeng GuoSecretary and Chief Financial Officer
Chaoyang YaoDeputy General Manager
Chun YeDeputy General Manager
Wentao HuangAccounting Supervisor